NCT05880394View on ClinicalTrials.gov

Study of Dotatate Imaging in Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2024

Conditions
Breast Cancer Stage IV
Interventions
DRUG

Gallium-68 DOTATATE

Gallium-68 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.

DRUG

Copper-64 DOTATATE

Copper-64 DOTATATE is a diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor expression on tumors.

Trial Locations (1)

92614

Hoag Memorial Hospital Presbyterian, Irvine

All Listed Sponsors
lead

Hoag Memorial Hospital Presbyterian

OTHER